skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8850

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil

Review

(3130) Views  (1312) Full article downloads

Authors: Carlos Ferrario

Published Date March 2009 Volume 2009:5 Pages 301 - 314
DOI: http://dx.doi.org/10.2147/VHRM.S3141

Carlos Ferrario

Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC, USA

Abstract: Endothelial dysfunction is the common link between cardiovascular disease risk factors and the earliest event in the cascade of incidents that results in target organ damage. Angiotensin II, the terminal pressor effector arm of the renin-angiotensin-aldosterone system, increases blood pressure (BP) by vasoconstriction and sodium and fluid retention, and has a pro-oxidative action that induces endothelial dysfunction and contributes to vascular remodeling. Angiotensin receptor blockers (ARBs) reduce BP and morbidity and mortality in patients with hypertension, ventricular hypertrophy, diabetes mellitus, and renal disease. Olmesartan medoxomil is a long-acting, well-tolerated, effective ARB that prevents or reverses endothelial dysfunction in animal models of atherosclerosis, hypertension, diabetes, nephropathy, and retinopathy. Olmesartan medoxomil, a prodrug of olmesartan approved for the treatment of hypertension, has been shown to ameliorate endothelial dysfunction in patients with hypertension or diabetes. In randomized studies, the drug reduces vascular inflammation and the volume of large atherosclerotic plaques, increases the number of regenerative endothelial progenitor cells in the peripheral circulation, improves endothelium-dependent relaxation, and restores the normal resistance vessel morphology. Importantly, the impact of olmesartan medoxomil on endothelial dysfunction is thought to be independent of BP lowering.

Keywords: endothelial dysfunction, angiotensin receptor blocker, olmesartan medoxomil, hypertension, atherosclerosis

 




 

Other articles by Dr Carlos Ferrario



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Comparative assessment of angiotensin receptor blockers in different clinical settings
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Role of olmesartan in combination therapy in blood pressure control and vascular function
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University